Observational Study to Assess the Efficacy and Safety of Bendamustine Plus Rituximab in Patients Affected by Chronic Lymphocytic Leukemia
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 16 Oct 2017
At a glance
- Drugs Bendamustine (Primary) ; Rituximab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 11 Oct 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Dec 2017.
- 11 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 24 May 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Sep 2017.